E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
Renato D. Lopes,Jennifer A. White,Pierluigi Tricoci,Harvey D. White,Paul W. Armstrong,Eugene Braunwald,Robert P. Giugliano,Robert A. Harrington,Basil S. Lewis,Gerard X. Brogan,C. Michael Gibson,Robert M. Califf,L. Kristin Newby +12 more
TL;DR: There was no preferential benefit of early vs. delayed provisional eptifibatide use for ischemic outcomes as age increased, but the incremental bleeding risk was amplified.
Journal ArticleDOI
Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis.
TL;DR: It is suggested that a trial of propranolol therapy be attempted prior to deciding upon operative treatment in patients with IHSS whose chief symptom is disabling angina pectoris.
Journal ArticleDOI
The Surgical Treatment of Calcific Aortic Stenosis Operative Methods and the Results of the Pre- and Postoperative Hemodynamic Assessments
Journal ArticleDOI
Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry).
Peter J. Sharis,Christopher P. Cannon,William J. Rogers,Carolyn H. McCabe,Sabina A. Murphy,C. Michael Gibson,Peter Stone,Eugene Braunwald +7 more
Journal ArticleDOI
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial:
Serge Korjian,Eugene Braunwald,Yazan Daaboul,Freek W.A. Verheugt,Christoph Bode,Michal Tendera,Purva Jain,Alexei N. Plotnikov,Paul Burton,C. Michael Gibson +9 more
TL;DR: Biomarker-positive patients with no prior history of stroke or transient ischemic attack may be a optimal target population to receive “dual pathway” therapy with rivaroxaban plus dual antiplatelet therapy for secondary prevention following ACS.